| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2005.08.038 |
| P698 | PubMed publication ID | 16188302 |
| P2093 | author name string | Verhoef S | |
| Lubsen-Brandsma MA | |||
| van Beurden M | |||
| Olivier RI | |||
| P2860 | cites work | Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 |
| Use of proteomic patterns in serum to identify ovarian cancer | Q30819686 | ||
| Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis | Q31005059 | ||
| Progress and challenges in screening for early detection of ovarian cancer | Q31041170 | ||
| CA 125 in benign gynecological conditions. | Q33608489 | ||
| Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up | Q34313361 | ||
| Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography | Q35187056 | ||
| Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study | Q36601557 | ||
| Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation | Q36620469 | ||
| A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results | Q47565502 | ||
| Screening for ovarian cancer: a pilot randomised controlled trial. | Q50644480 | ||
| Prospectively detected cancer in familial breast/ovarian cancer screening. | Q50654339 | ||
| The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. | Q50660552 | ||
| Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. | Q52123195 | ||
| Early detection of familial ovarian cancer. | Q52891983 | ||
| The performance of screening tests for ovarian cancer: results of a systematic review | Q57462924 | ||
| Ultrasound screening for familial ovarian cancer | Q67764093 | ||
| A combined approach for the early detection of ovarian cancer in asymptomatic women | Q71323460 | ||
| The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer | Q72361866 | ||
| Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center | Q72617408 | ||
| Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter | Q73916685 | ||
| Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles | Q74662201 | ||
| Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers | Q77204834 | ||
| Use of CA-125 and ultrasound in high-risk women | Q77676299 | ||
| Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing | Q79214311 | ||
| Biology of epithelial ovarian cancer: implications for screening women at high genetic risk | Q79840800 | ||
| P433 | issue | 1 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 20-26 | |
| P577 | publication date | 2005-09-26 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer | |
| P478 | volume | 100 |
| Q33561005 | A hospital-based case-control study of identifying ovarian cancer using symptom index |
| Q30431721 | A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study |
| Q37724409 | Accuracy of ovarian and colon cancer risk assessments by U.S. physicians. |
| Q24651567 | Beyond CA125: the coming of age of ovarian cancer biomarkers |
| Q33859857 | CA125 in ovarian cancer |
| Q63446328 | Combined use of biomarkers for detection of ovarian cancer in high-risk women |
| Q37324647 | Combining a symptoms index with CA 125 to improve detection of ovarian cancer. |
| Q51117431 | Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. |
| Q46233339 | Could a pelvic and abdominal symptom index assist in early detection of ovarian cancer? |
| Q36462856 | Development of Follicle-Stimulating Hormone Receptor Binding Probes to Image Ovarian Xenografts |
| Q100433539 | Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations |
| Q39777813 | Development of an ovarian cancer symptom index: possibilities for earlier detection. |
| Q64068427 | Diagnostic Value of Cytology in Detecting Endometrial Hyperplasia and Endometrial and Ovarian Cancers in Patients Undergoing Hysterectomy or Salpingo-Oophorectomy |
| Q37024691 | Differential methylation profile of ovarian cancer in tissues and plasma |
| Q82682167 | Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? |
| Q38988184 | Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials |
| Q37348465 | Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer |
| Q36178261 | Endometrial and ovarian cancer in lynch syndrome |
| Q38964976 | Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study |
| Q90131207 | Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations |
| Q35773039 | Genetic counseling content: How does it impact health behavior? |
| Q37242239 | Genomic Biomarkers for Breast Cancer Risk |
| Q83525183 | Hereditary breast and ovarian cancer syndrome |
| Q34977063 | Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management |
| Q55297626 | Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach. |
| Q40247920 | Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population. |
| Q38073703 | Management of genetic syndromes predisposing to gynecologic cancers |
| Q36610368 | No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study |
| Q36894026 | Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer |
| Q79416180 | Ovarian cancer symptom index: possibilities for earlier detection |
| Q90330482 | Ovarian cancer: Current status and strategies for improving therapeutic outcomes |
| Q34960174 | Potential markers for detection and monitoring of ovarian cancer. |
| Q91413388 | Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study |
| Q50787069 | Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. |
| Q35596203 | Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests. |
| Q22252596 | The clinical management of BRCA1 and BRCA2 mutation carriers |
| Q54997659 | The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform |
| Q36240959 | The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy |
| Q60143318 | Tumors of the Female Reproductive Organs |
| Q33820594 | Two decades after BRCA: setting paradigms in personalized cancer care and prevention |
Search more.